Báo cáo khoa học: A novel splicing variant form suppresses the activity of full-length signal transducer and activator of transcription 5A pot

A novel splicing variant form suppresses the activity of full-length signal transducer and activator of transcription 5A Yoshihisa Watanabe1, Masaya Ikegawa2, Yoshihisa Naruse3 and Masaki Tanaka1 Department of Cell Biology, Research Institute for Neurological Diseases and Geriatrics, Kyoto Prefectural University of Medicine, Japan Department of Genomic Medical Sciences, Kyoto Prefectural University of Medicine, Japan Department of Anatomy, Medical Education and Research Center, Meiji University of Integrative Medicine, Kyoto, Japan Keywords brainstem; coaggregation; STAT5A splicing variant; suppression of STAT5A activity Correspondence M Tanaka, Department of Cell Biology, Research Institute for Neurological Diseases and Geriatrics, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamikyo-ku, Kyoto 602-0841, Japan Tel ⁄ Fax: +81 75 251 5797 E-mail: mtanaka@koto.kpu-m.ac.jp Database The nucleotide sequence for the mouse STAT5A_DE18 cDNA has been submitted to the GenBank database under the accession number EU249543 (Received July 2009, revised 24 August 2009, accepted September 2009) Signal transducers and activators of transcription (STATs) regulate a variety of cellular functions, including differentiation and proliferation STAT3 and STAT5 are known to play important roles in brain processes, such as energy homeostasis and neuronal development We isolated a novel splicing variant of STAT5A from a cDNA library of the mouse brainstem This variant, STAT5A_DE18, lacked exon 18 and caused a frameshift in the C-terminus, resulting in deletion of a tyrosine phosphorylation site and a transactivation domain Although the frameshift region had no characteristic motifs, it was highly serine ⁄ threonine-rich and contained a short proline-rich sequence Expression of STAT5A_DE18 was detected in the mouse brainstem, lung and thymus, but not in the mouse cerebrum or cerebellum We developed a specific antibody against STAT5A_DE18 and investigated the intracellular localization of this variant STAT5A_DE18 showed dot-like structures in the cytoplasm and could not translocate into the nucleus after prolactin treatment STAT5A_DE18 showed a strong tendency to aggregate, which led to coaggregation with STAT5A_full-length This coaggregation inhibited the nuclear transport of STAT5A and suppressed prolactin-induced activation of STAT5A doi:10.1111/j.1742-4658.2009.07339.x Introduction Signal transducers and activators of transcription (STATs) are cytoplasmic transcriptional factors that respond to cytokines, growth factors, and peptide hormones [1,2] In mammals, seven members of the STAT family (STAT1–4, STAT5A, STAT5B, and STAT6) have been identified STATs are activated through the phosphorylation of a tyrosine residue located between a Src homology (SH2) domain and a transactivation domain Phosphorylated STATs form homodimers, heterodimers, or tetramers, and translocate into the nucleus, where they act as transcription activators [3–6] In addition to the involvement of STATs in immunological intracellular signal transduction, hematopoiesis, mammary gland development, and lactogenesis [7], some reports have demonstrated that STAT3 and STAT5 also play important roles in the central Abbreviations DAPI, 4¢,6-diamidino-2-phenylindole; EGFP, enhanced green fluorescent protein; GST, glutathione S-transferase; MTT, 3-(4,5-dimethylthiazol2-yl)-2,5-diphenyl-tetrazolium bromide; PRL, prolactin; SH2, Src homology 2; STAT, signal transducer and activator of transcription; STAT5A_FL, signal transducer and activator of transcription 5A_full-length 6312 FEBS Journal 276 (2009) 6312–6323 ª 2009 The Authors Journal compilation ª 2009 FEBS Y Watanabe et al nervous system [8–10] Morphological analyses of STAT5 knockout mice revealed a reduction in the number of cortical interneurons in the marginal zone, abnormalities of corticofugal axon projection, and defective axon guidance [8] Furthermore, neuronal cell-specific suppressor cytokine signaling-3 (SOCS3) knockout mice exhibit higher leptin-induced phosphorylation of hypothalamic STAT3, loss of body weight, and suppression of food intake [9] STAT5 was also reported to be involved in energy homeostasis Neuron-specific STAT5A and STAT5B knockout mice develop severe obesity with hyperphagia, impaired thermal regulation in response to cold, hyperleptinemia, and insulin resistance [10] These reports indicate that STAT3 and STAT5 regulate food intake and energy utilization in the brain We previously analyzed the functions and expression of relaxin 3, which is involved in stress responses and hyperphagia [11–13] Relaxin is expressed in neurons of the nucleus incertus of the median dorsal tegmental pons, and its expression is regulated by corticotropinreleasing factor [11,14] Relaxin 3-expressing neurons project into the septum, hippocampus and feedingassociated regions such as the lateral hypothalamus area and arcuate nucleus [11] Recently, we determined the promoter region of the relaxin gene, and found that it contained a putative binding site for STATs [14] In an attempt to analyze this transcriptional regulation, we isolated a novel splicing variant of STAT5A, STAT5A_DE18, from a cDNA library of the mouse brainstem The variant protein was generated by a frameshift in the C-terminal region, resulting in deletion of the tyrosine phosphorylation site and transactivation domain Here, we report that this variant is predominantly expressed in the brainstem and coaggregates with STAT5A_full length (STAT5A_FL) Furthermore, the expression of this variant suppresses the activity of STAT5A Results Isolation of a novel STAT5A splicing variant A cDNA encoding STAT5A was cloned from the mouse brainstem to investigate transcriptional regulation by STAT5 in the brain During the process of STAT5A cDNA cloning, we found a novel splicing variant of STAT5A by nucleotide sequencing analysis The mouse STAT5A gene is composed of 20 exons that encode a 793 amino acid polypeptide with a calculated molecular mass of 91 kDa (Fig 1A, STAT5A_FL) The novel splicing variant, termed STAT5A_DE18, lacked the sequence corresponding to A novel variant form suppresses full-length STAT5A exon 18 of STAT5A The deletion of exon 18 caused a frameshift at Ala688, which led to premature termination at the codon for amino acid 798 (Fig 1A, STAT5A_DE18) The C-terminal region of the variant lacked the transactivation domain and the tyrosine residue (Tyr694) phosphorylated by Janus protein tyrosine kinase or other tyrosine kinases, although the DNA-binding domain and SH2 domain remained intact The frameshift region of STAT5A_DE18 (amino acids 688–797) had no characteristic motifs However, it was highly serine ⁄ threonine-rich (25.5%) and had a short proline-rich sequence [PQMPEPAPP(693–701)] RT-PCR analysis of STAT5A_DE18 To determine the expression of STAT5A_DE18 in mouse tissues, RT-PCR analyses were conducted using specific primers designed within exons 16 and 20 (Fig 1A) The RT-PCR analyses were expected to generate a 387 bp fragment for STAT5A_DE18 and a 439 bp fragment for STAT5A_FL The PCR product of STAT5A_FL was detected in multiple tissues, such as the cerebrum, kidney, and liver (Fig 1B) On the other hand, the PCR product of STAT5A_DE18 was detected in the brainstem, heart and lung, and thymus (Fig 1B), but not in the cerebrum or cerebellum Expression of the variant was also observed in the N2a mouse neuroblastoma cell line (Fig 1B) The genomic structure of STAT5A is highly conserved in humans and mice Human STAT5A has 20 exons, and exon 18 consists of 52 bp, similar to the case for mouse STAT5A Therefore, we examined whether the splicing variant was expressed in the human brainstem To minimize the amplification of STAT5B, the analysis was performed by nested RT-PCR (Fig 2A) Human brainstem cDNAs were synthesized from total RNA extracts of the human pons The first PCR amplification was performed using STAT5A-specific primers designed within the 5¢-UTR and 3¢-UTR Using the first-round PCR products as templates, the second PCR amplification was performed The 411 bp product for STAT5A_DE18 was detected in the human pons and mouse brainstem by nested RT-PCR (Fig 2A, lanes and 3) Furthermore, we reconfirmed that this variant was not expressed in the mouse cerebrum (Fig 2A, lane 1) In the case of human STAT5A_DE18, deletion of exon 18 caused a frameshift at Ala688, which led to a premature stop codon at amino acid 690, resulting in a truncated C-terminus Human STAT5A_DE18 was shorter than the STAT5Ab isoform, encoded by another splicing FEBS Journal 276 (2009) 6312–6323 ª 2009 The Authors Journal compilation ª 2009 FEBS 6313 A novel variant form suppresses full-length STAT5A A Y Watanabe et al Mouse STAT5A gene ΔE18 exon 18 1kb (52 bp) α-helical coiled-coil STAT5A_FL TransSH2 Y694 activation DNA binding 793 amino acids 688 STAT5A_ΔE18 Δ 797 amino acids Pro-rich (693-701) B (bp) 500 400 300 10 11 12 13 FL (439 bp) ΔE18 (387 bp) G3PDH Fig Gene structure and expression of a novel STAT5A splicing variant (A) The mouse STAT5A gene contains 20 exons The translation initiation codon and stop codon are located in exons and 20, respectively STAT5A_FL encodes a 793 amino acid protein composed of a a-helical coiled-coil domain, a DNA-binding domain, an SH2 domain, and a C-terminal transactivation domain The deletion of exon 18 (52 bp) in the STAT5A_DE18 mRNA results in a translational frameshift from Ala688 The STAT5A_DE18 protein lacks the Tyr694 phosphorylation site and transactivation domain, and contains a new reading frame with a proline-rich sequence (amino acids 693–701) (B) The expression of STAT5A_DE18 in mouse tissues was analyzed by RT-PCR PCR was performed using primers designed in exons 16 and 20 (A, arrows) The RT-PCR analyses were expected to generate a 439 bp fragment for STAT5A_FL and a 387 bp fragment for STAT5A_DE18 (upper panel) RT-PCR amplification of glyceraldehyde-3-phosphate dehydrogenase (G3PDH) is indicated as an internal control (lower panel) Lane 1: cerebrum Lane 2: brainstem Lane 3: cerebellum Lane 4: heart Lane 5: lung Lane 6: kidney Lane 7: liver Lane 8: thymus Lane 9: mammary gland Lane 10: adrenal gland Lane 11: N2a cell line Lane 12: STAT5A_FL cDNA Lane 13: STAT5A_DE18 cDNA variant of STAT5A, and also lacked the transactivation domain and tyrosine residue (Fig 2B) Immunoblotting and immunocytochemical analyses of STAT5A_DE18 To examine the expression and the intracellular localization of STAT5A_DE18, we produced a polyclonal antibody against STAT5A_DE18 A rabbit was immunized with a glutathione S-transferase (GST)– STAT5A_DE18_C fusion protein, and a polyclonal antibody against STAT5A_DE18 was affinity-purified using a thioredoxin–STAT5A_DE18_C-immobilized column We performed immunoblotting analyses to examine the specificity of the antibody The antibody specifically detected exogenous Flag–STAT5A_DE18, and did not cross-react with STAT5A_FL (Fig 3) The antibody was subsequently used for immunoblotting and immunocytochemistry of STAT5A_DE18 In order to examine its intracellular localization, Flag– STAT5A_DE18 or Flag–STAT5A_FL was transiently expressed in HeLa cells, and the cells were immunostained with antibodies against STAT5A_DE18 or 6314 STAT5A_FL Flag–STAT5A_DE18 exhibited a dotlike localization in HeLa cells (Fig 4B), whereas Flag– STAT5A_FL was diffusely localized to the cytoplasm and nucleus (Fig 4A) To confirm that this unusual localization of STAT5A_DE18 was not due to overexpression of Flag–STAT5A_DE18 in HeLa cells, we generated HeLa cells stably expressing a STAT5A_DE18–enhanced green fluorescent protein (EGFP) fusion protein The localization of this fusion protein in the stably transfected cells was similar to that observed in the transiently transfected cells Confocal laser microscopy revealed that some dot-like structures colocalized with LysoTracker Red, a lysosomal marker (Fig 4C) However, the dot-like structures did not colocalize with markers for mitochondria or the endoplasmic reticulum (data not shown) These results indicated that STAT5A_DE18 was localized in the cytoplasm as dot-like structures Next, the nuclear transport of STAT5A_DE18 was investigated using an EGFP fusion protein An expression vector for STAT5A_FL–EGFP or STAT5A_DE18–EGFP was transfected in T47D cells, which endogenously express the prolactin (PRL) receptor [15,16] STAT5A_FL– FEBS Journal 276 (2009) 6312–6323 ª 2009 The Authors Journal compilation ª 2009 FEBS Y Watanabe et al A novel variant form suppresses full-length STAT5A A B kDa 83 kDa -C M pF lag V-6 a -S TA pF T5 lag A -S TA _FL T5 A_ ΔE The characteristic localization of STAT5A_DE18 suggested that this protein may form aggregates Therefore, we investigated whether it could form insoluble aggregates Flag–STAT5A_DE18 was exogenously expressed in HeLa or N2a cells, and its solubility in the detergent Triton X-100 was examined Transfected cells were separated into 0.5% Triton X-100-soluble and 0.5% Triton X-100-insoluble fractions, and the amounts of Flag–STAT5A_DE18 in the fractions were quantified by immunoblotting with the antibody against STAT5A_DE18 Flag–STAT5A_DE18 was recovered only in the insoluble fractions (Fig 6A), confirming that the dot-like structures were aggregates of STAT5A_DE18 Furthermore, we examined whether endogenous STAT5A_FL was also present in these aggregates, as other STAT isoforms, namely STAT3b and STAT5b, form heterodimers with their full-length forms [17,18] To this end, the soluble and insoluble fractions were analyzed by immunoblotting with the antibody against STAT5A_FL In the STAT5A_DE18expressing cells, endogenous STAT5A_FL was recov- pF la g Aggregate formation by STAT5A_DE18 ered not only in the soluble fractions but also in the insoluble fractions (Fig 6A) These findings were confirmed by immunocytochemistry N2a cells transfected with the expression plasmids for STAT5A_ DE18–EGFP and Flag–STAT5A_FL were immunostained with the antibody against STAT5A_FL STAT5A_DE18–EGFP formed massive aggregates in N2a cells (Fig 6C, arrows) In EGFP-positive cells, coexpressed STAT5A_FL was also localized to massive -C M pF lag V-6 a -S T pF lag AT5 A -S TA _F T5 L A_ ΔE 18 EGFP was translocated into the nucleus after PRL treatment (Fig 5A,B), whereas the dot-like structures of STAT5A_DE18–EGFP remained in the cytoplasm despite PRL treatment (Fig 5C,D) pF lag Fig Human STAT5A_DE18 variant (A) Expression of STAT5A_DE18 in the human brainstem was confirmed by nested RTPCR In the first PCR amplification, mouse and human STAT5A were specifically amplified using primers designed within the 3¢-UTR and 5¢-UTR The second PCR amplification was expected to generate a 411 bp fragment for STAT5A_DE18 and a 463 bp fragment for STAT5A_FL Lane 1: mouse cerebrum Lane 2: mouse brainstem Lane 3: human pons Lane 4: mouse STAT5A_FL plasmid Lane 5: mouse STAT5A_DE18 plasmid Size markers (M) are shown on the left (B) Comparisons of the mouse and human amino acid sequences of STAT5A_FL, STAT5A_DE18, and STAT5Ab The frameshift regions of STAT5A_DE18 are underlined Shaded letters, bold letters and the open box show the proline-rich region, tyrosine phosphorylation residues, and SH2 domains, respectively FL 83 Anti-STAT5A_FL ΔE18 Anti-STAT5A_ΔE18 Fig Immunoblotting analysis of STAT5A_DE18 The immunoreactivity of the polyclonal antibody against STAT5A_DE18 was confirmed by immunoblotting analysis HeLa cells were transfected with a control vector (pFlag–CMV-6a), pFlag–STAT5A_FL or pFlag– STAT5A_DE18 for 48 h Immunoblotting analyses of the cell extracts were performed with polyclonal antibody against STAT5A_FL (left panel) or STAT5A_DE18 (right panel) FEBS Journal 276 (2009) 6312–6323 ª 2009 The Authors Journal compilation ª 2009 FEBS 6315 A novel variant form suppresses full-length STAT5A Y Watanabe et al aggregates (Fig 6B,D, arrows) This coaggregation was not observed in cells expressing STAT5A_FL alone (Fig 6, arrowheads) These results indicate that expression of STAT5A_DE18 leads to coaggregation with STAT5A_FL A STAT5A_DE18 suppresses STAT5A activity Flag-FL B Flag- Δ E18 C Δ E18-EGFP 6316 We investigated whether the aggregation affected cell viability or the transcriptional activity of STAT5A The viabilities of STAT5A_DE18-expressing cells were measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) and dead cell protease-based cytotoxicity assays In the MTT assays, overexpression of STAT5A_DE18 did not decrease the viability of N2a cells as compared with the vector control, even at 48 h after transfection (Fig 7A) Furthermore, the dead cell protease-based cytotoxicity assay, which is highly sensitive, confirmed that there was no significant difference in the viability of STAT5A_DE18-expressing cells (Fig 7B) Next, the transcriptional activity of STAT5A was measured in T47D cells, which express STAT5A_DE18 exogenously A luciferase reporter gene joined to the mouse b-casein promoter containing a c-activated sequence was constructed to monitor the activity of STAT5A In vector-transfected T47D cells, PRL stimulation resulted in a 3.3-fold increase in reporter gene expression (Fig 7C) On the other hand, expression of STAT5A_DE18 reduced the activation of PRL-stimulated STAT5A to  2.2-fold (Fig 7C) The expression of STAT5A_DE18 suppressed the PRLinduced activity of STAT5A by 33% Furthermore, we observed nuclear translocation of STAT5A_FL by immunocytochemistry using the antibody against STAT5A_FL T47D cells were transfected with Flag–STAT5A_FL alone (Fig 7D, upper panel) or both Flag–STAT5A_FL and STAT5A_DE18–EGFP (Fig 7D, lower panel), and this was followed by incubation with or without PRL for 24 h After fixation, the cells were immunostained with the antibody against Fig Immunocytochemistry of STAT5A_DE18 The HeLa cells expressing Flag–STAT5A_FL (A) or Flag–STAT5A_DE18 (B) were analyzed by immunocytochemistry using the antibodies against STAT5A_FL or STAT5A_DE18 (green) Nuclei were stained with DAPI (blue) The small panels on the right represent the immunocytochemical images of untransfected HeLa cells Bar: 20 lm (C) HeLa cells were stably transfected with pEGFP–STAT5A_DE18 Living cells were stained with LysoTracker Red (red), and observed using a confocal laser microscope STAT5A_DE18–EGFP (green) is detected as dot-like structures and localized to the cytoplasm A few dots of STAT5A_DE18–EGFP are colocalized with the lysosome marker (arrows) Bar: 20 lm FEBS Journal 276 (2009) 6312–6323 ª 2009 The Authors Journal compilation ª 2009 FEBS Y Watanabe et al A novel variant form suppresses full-length STAT5A +PRL -PRL E18-EGFP FL-EGFP A B * C D * * * E EGFP * * F * * * * Fig Nuclear transport analysis of STAT5A_DE18 (A–D) STAT5A_FL–EGFP (A, B), STAT5A_DE18–EGFP (C, D), or EGFP (E, F) were transiently expressed in T47D cells Cells were cultured in serum-free medium with (+) or without ()) PRL (10 ngỈmL)1) for h, and observed under a fluorescence microscope Asterisks indicate nuclei Bar: 20 lm STAT5A_FL and observed by fluorescence microscopy When cells were transfected with Flag–STAT5A_FL alone, Flag–STAT5A_FL predominantly translocated into the nucleus after PRL treatment (Fig 7D, upper right panel) In cotransfected cells, the PRL-induced translocation of Flag–STAT5A_FL into the nucleus was inhibited by its coaggregation with STAT5A_DE18–EGFP (Fig 7D, lower right panel) These results are consistent with the hypothesis that aggregation of STAT5A_DE18 suppresses the transcriptional activity of STAT5A Discussion We isolated a novel STAT5A splicing variant from the mouse brainstem The STAT5A_DE18 variant lacked the transactivation domain and a tyrosine residue Many STAT isoforms have previously been reported to be generated by alternative splicing and proteolytic processing [17,19] STAT1, STAT3, STAT4, STAT5A and STAT5B mRNAs are alternatively spliced at the 3¢-end, resulting in the production of b-isoforms truncated at the transactivation domain STAT5A b-isoforms and STAT5B b-isoforms are generated by insertion of intron 18, and lack only the transactivation domain [18,20] These STAT b-isoforms are phosphorylated on the tyrosine residue after stimulation by cytokines or hormones, and translocate into the nucleus, but fail to activate transcription [18,21] Unlike the b-isoforms, the STAT5A_DE18 variant was not phosphorylated, because it lacked the tyrosine residue Moreover, STAT5A_DE18 did not translocate into the nucleus in T47D cells after PRL treatment, indicating a distinct property of STAT5A_DE18 as compared with the b-isoforms However, STAT5A_DE18 clearly suppressed the activity of STAT5A, similar to the case for the b-isoforms It has been reported that the phosphorylated b-isoforms form heterodimers with full-length STATs and decrease their activities [18] These heterodimers can translocate into the nucleus and bind to target sequences on DNA, but fail to activate transcription [18] On the other hand, we demonstrated that the STAT5A_DE18-mediated suppression was caused by coaggregation of STAT5A_FL and STAT5A_DE18 in cultured cells, although the precise mechanism for the coaggregation remains to be determined It is known that unphosphorylated STAT5A monomers can dimerize via interactions between their b-barrel (amino acids 332– 470) and four-helix bundle (amino acids 138–331) domains [22] STAT5A_DE18 also contains these domains, suggesting that heterodimers of unphosphorylated STAT5A_FL and STAT5A_DE18 are probably formed in the soluble condition prior to their coaggregation This coaggregation could be the cause of the decrease in functional STAT5A, resulting in suppressed transcription of its downstream genes STAT5Ab is expressed in early myeloid lineages [23], whereas the STAT5A_DE18 variant was expressed in the mouse brainstem, thymus, and lung Moreover, exon of STAT5A is alternatively spliced by heterogeneous ribonucleoprotein L-like at the transition from naă ve to activated T-cells [24] STAT5A transcripts variously undergo tissue-specific or cell type-specific alternative splicing, suggesting that these variants are involved in specific functions The physiological role of STAT5A_DE18 may involve the regulation of STAT5 function in the brainstem, considering that STAT5A_DE18 suppresses the activity of STAT5 The functions of STAT5 in the central nervous system have recently been reported Intracerebroventricular administration of granulocyte–macrophage colony-stimulating factor and leptin activated neuronal STAT5 and reduced food intake [10,25] The activation of STAT5 following leptin administration was observed not only in the hypothalamus but also in areas of the brainstem, such as the raphe obscurus, raphe pallidus, dorsal motor nucleus of the vagus, and solitary tract FEBS Journal 276 (2009) 6312–6323 ª 2009 The Authors Journal compilation ª 2009 FEBS 6317 A novel variant form suppresses full-length STAT5A Y Watanabe et al A B C D E F G Fig Aggregate formation of STAT5A_DE18 and STAT5A_FL (A) pFlag–STAT5A_DE18 or control vector was transfected into N2a (left panels) or HeLa (right panels) cells The Triton X-100-soluble (S) and Triton X-100-insoluble (P) fractions were analyzed by immunoblotting with antibody against STAT5A_DE18 (upper panels) or antibody against STAT5A_FL (lower panels) N2a cells were transfected with Flag–STAT5A_FL and STAT5A_DE18–EGFP (B–D) or Flag–STAT5A_FL alone (E–G) Flag–STAT5A_FL was detected with a primary antibody against STAT5A_FL and Alexa Fluor 546-conjugated secondary antibody (B, E) The localization of STAT5A_DE18–EGFP was observed under a fluorescence microscope (C, F) The merged image containing DAPI staining (blue) is shown in (D) and (G) Colocalization of the signals appears yellow Bar: 20 lm nucleus [25] Furthermore, neuron-specific STAT5A and STAT5B knockout mice develop severe obesity with hyperphagia, impaired thermal regulation in response to cold, hyperleptinemia, and insulin resistance [10] These STAT5-mediated functions in the central nervous system may be controlled by STAT5A_DE18 From the results of RT-PCR and immunoblotting analyses, however, the expression level of STAT5A_DE18 seemed to be very low in the normal brain Furthermore, this variant protein tended to form aggregates even in stably transfected cells, suggesting that high-level expression of this variant might lead to pathological conditions The formations of aggregates and inclusion bodies in the brain are 6318 pathognomonic features of many neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease [26,27] Recent studies have revealed that mutant huntingtin aggregates interact with several transcription factors, such as CREBbinding protein, TATA-binding protein, and NF-Y, resulting in reduced expression of their target genes [28,29] This inhibition of functional transcription factors may be associated with the normal functions of huntingtin and ⁄ or involved in the pathology of Huntington’s disease We observed that the transcriptional activation of STAT5A_FL was suppressed by STAT5A_DE18 aggregates Moreover, it has been reported that defective mutations of STAT5B are involved in FEBS Journal 276 (2009) 6312–6323 ª 2009 The Authors Journal compilation ª 2009 FEBS Y Watanabe et al A novel variant form suppresses full-length STAT5A A B C D Fig Viability and reporter analysis (A, B) N2a or HeLa cells were transfected with pFlag–STAT5A_FL, pFlag–STAT5A_DE18 or control vector (pFlag–CMV-6a) in serum-containing medium After transfection, the cell viability was assessed by MTT (A) and cytotoxicity (B) assays As a positive control, the viability of rotenone-treated cells was also measured (C) T47D cells were transfected with pFlag–STAT5A_FL, pFlag–STAT5A_DE18 or control vector (pFlag–CMV-6a), as well as with pCasein-luc and pSV40-Rluc The cells were treated with PRL (10 ngỈmL)1), and this was followed by measurement of the luciferase activities These results are shown as the means ± standard deviation of three experiments *P < 0.05 versus control cells without PRL stimulation Statistical analyses were performed using ANOVA with Tukey’s HSD post hoc test (D) T47D cells were transfected with pFlag–STAT5A_FL alone (upper panels) or together with pEGFP–STAT5A_DE18 (lower panels) The cells were then incubated with (+) or without ()) PRL (10 ngỈmL)1) for 24 h, and this was followed by immunocytochemical analysis using a primary antibody against STAT5A_FL and Alexa Fluor 546-conjugated secondary antibody Nuclei are indicated by asterisks DE18–EGFP–positive and DE18–EGFP-negative cells are indicated by arrows and arrowheads, respectively Bar: 20 lm the syndrome of growth hormone insensitivity [30,31] Considering the specific expression of STAT5A_DE18 in the brainstem and its suppression of STAT5 activ- ity, accumulation of STAT5A_DE18 may be pathogenically involved in certain neurological disorders This possibility will be investigated in future studies FEBS Journal 276 (2009) 6312–6323 ª 2009 The Authors Journal compilation ª 2009 FEBS 6319 A novel variant form suppresses full-length STAT5A Y Watanabe et al Experimental procedures Cell culture and transfection N2a and HeLa cells were routinely maintained in Ham’s F12 medium containing 10% fetal bovine serum The human breast cancer T47D cell line was cultured in RPMI1640 medium containing 10% fetal bovine serum [32] To generate a stable cell line, transfected HeLa cells were passaged into medium containing G418 (400 lgỈmL)1) for 10 days A stable cell line expressing STAT5A_DE18– EGFP was isolated from the pool of cells by limiting dilution cloning, and maintained in the same medium Plasmids Mouse STAT5A_FL and STAT5A_DE18 cDNAs were cloned into the pGEM-T easy plasmid (Promega, Madison, WI, USA) by PCR, using the primers 5¢-CCGTCAGGA GCCGTCAGAAG-3¢ and 5¢-CCTGGCGCAAGAACTGA CAC-3¢ For these amplifications, cDNA libraries from the mouse brainstem and breast were prepared as previously described [33] Briefly, total RNA was extracted from C57BL ⁄ 6N mouse tissues using TRIzol (Invitrogen, Carlsbad, CA, USA), and cleaned up with an RNeasy Micro Kit (Qiagen, Hilden, Germany) cDNAs were synthesized with a ThermoScript RT-PCR System (Invitrogen), using an oligo-dT primer Flag-tagged STA5A_FL and STAT5A_DE18 constructs were generated by PCR using the primers 5¢-GA ATTCTATGGCGGGCTGGATTCAG-3¢ and 5¢-GTCG ACCTACAACTGACGTGGGC-3¢ The PCR fragments were cloned into pGEM-T easy, and this was followed by subcloning into the EcoRI–SalI site of pFlag–CMV6a (Sigma-Aldrich, St Louis, MO, USA) STAT5A_DE18– EGFP was constructed by PCR using the primers 5¢-GA ATTCGCCACCATGGCGGGCTGGATTC-3¢ and 5¢-CC CGGGCCAACTGACGTGGGCTCC-3¢, and the resulting PCR product containing a Kozak sequence was cloned into pGEM-T easy The EcoRI–SmaI fragment of this plasmid was subcloned into the EcoRI–SmaI site of pEGFP-N1 (TaKaRa Bio, Otsu, Japan) For construction of a reporter plasmid (pCasein-luc), the mouse b-casein promoter was inserted into the firefly luciferase reporter gene by PCR using the primers 5¢-CTTCATAACTGAGGTTAAAGC C-3¢ and 5¢-GTCCTATCAGACTCTGTGAC-3¢ PCR analysis To analyze the expression of mouse STAT5A_DE18, we designed the specific primers 5¢-CTGCGCTTCAGT GACTCGGA-3¢ and 5¢-CGTGCCTGGCAACATCCAT G-3¢, located within exons 16 and 20, respectively Furthermore, we confirmed the expression of mouse and human STAT5A_DE18 by nested RT-PCR analysis As a first step, 6320 STAT5A containing the 5¢-UTR and 3¢-UTR was specifically amplified from cDNA libraries of the human pons (TaKaRa Bio) and mouse brainstem, using the primers 5¢ -CTGCTCTCCGCTCCTTCCTG-3¢ ⁄ 5¢-CAGAGAGTCTG GAGTCCACG-3¢ and 5¢-CCGTCAGGAGCCGTCAGAA G-3¢ ⁄ 5¢-GACGTGGGCTCCTCACACTG-3¢, respectively The PCR amplification was performed with 35 cycles of 95 °C for 15 s and 60 °C for 180 s Using the resulting PCR products as templates, we examined the existence of exon 18 The primers 5¢-GACCTGCTCATCAACAAGCC -3¢ and 5¢-CATCCATGGTCTCATCCAGG-3¢ were used for a second round of PCR amplification The second round of PCR amplification was performed with 35 cycles of 95 °C for 15 s and 60 °C for 45 s All PCR amplifications were performed using Z-Taq DNA polymerase (TaKaRa Bio) Production of an antibody against STAT5A_DE18 To raise mouse STAT5A_DE18-specific antisera, we used the C-terminal region of STAT5A_DE18 (amino acids 688– 797), which was not found in STAT5A_FL A cDNA encoding this unique region, STAT5A_DE18_C, was inserted into the EcoRI–XhoI site of pGEX-6P-1 (GE Healthcare, Little Chalfont, UK) or the EcoRI–SalI site of pThioHisA (Invitrogen), using the primers 5¢-GGAT CCGGTTCGTCAATGCATCC-3¢ and 5¢-CTCGAGCTAC AACTGACGTGGGCTCCTCAC-3¢ Expression of the GST–STAT5A_DE18_C and thioredoxin–STAT5A_DE18_C fusion proteins was induced in Escherichia coli by treatment with mm isopropyl b-d-1-thiogalactopyranoside for h at 37 °C Inclusion bodies containing these proteins were recovered by centrifugation (20 000 g for 20 at °C), and washed with NaCl ⁄ Pi containing 0.5% Triton X-100 and mm phenylmethanesulfonyl fluoride The purified inclusion bodies were separated by SDS ⁄ PAGE, using a 12.5% gel, and the GST–STAT5A_DE18_C in the polyacrylamide gel was emulsified with Freund’s Complete Adjuvant (Difco Laboratories, Detroit, MI, USA) To produce an antiserum, a Kbl:NZW rabbit was immunized with this emulsion (Kitayama Labes, Ina, Japan) At weeks after the immunization, the antiserum was recovered and subjected to a titration assay For affinity purification of the antibody against STAT5A_DE18, inclusion bodies of thioredoxin–STAT5A_DE18_C were solubilized in 50 mm phosphate buffer (pH 8.5) containing m urea and mm phenylmethanesulfonyl fluoride, and rapidly refolded by 10-fold dilution in 50 mm phosphate buffer (pH 8.5) The soluble thioredoxin–STAT5A_DE18_C was purified with HiTrap Q HP (GE Healthcare) and immobilized on HiTrap NHS-activated HP (GE Healthcare) The antiserum was loaded onto this affinity column, and this was followed by washing with m NaCl and 1% Triton X-100 The antibody against STAT5A_DE18 was eluted with 100 mm FEBS Journal 276 (2009) 6312–6323 ª 2009 The Authors Journal compilation ª 2009 FEBS Y Watanabe et al glycine-HCl (pH 2.8), and this was followed by rapid neutralization The specificity of the purified antibody was confirmed by immunoblotting analysis A novel variant form suppresses full-length STAT5A and emission was recorded through a BP 500–530 nm filter Red-emitting dyes were excited with a 543 nm helium–neon laser, and emission was recorded through an LP 560 nm filter Immunoblotting Cells were washed with NaCl ⁄ Pi and extracted with ice-cold NaCl ⁄ Pi containing 0.5% Triton X-100 and a protease inhibitor cocktail (Nacalai Tesque, Kyoto, Japan) After sonication, each sample was fractionated by centrifugation (20 000 g, 15 min, °C), and the supernatant was recovered as a soluble fraction The precipitate was washed with ice-cold NaCl ⁄ Pi and recovered as an insoluble fraction These fractions were extracted in Laemmli buffer and separated by SDS ⁄ PAGE, using a 12.5% gel; this was followed by electroblotting onto poly(vinylidene difluoride) membranes (Millipore, Billerica, MA, USA) After blocking, the membranes were incubated with a polyclonal antibody against STAT5A_FL (1 : 1000 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or the polyclonal antibody against STAT5A_DE18 (1 : 500 dilution) for 12 h at 25 °C The membranes were then incubated with alkaline phosphatase-conjugated anti-rabbit IgG (1 : 5000 dilution; Millipore) for h Immunopositive signals were detected with the nitroblue tetrazolium chloride and 5-bromo-4chloro-3¢-indolylphosphatase p-toluidine salt reagents Immunocytochemistry N2a and HeLa cells (1 · 105) were plated on round cover glasses (13 mm in diameter), and transfected with pFlag– STAT5A_FL and pSTAT5A_DE18–EGFP, using Lipofectamine LTX (Invitrogen) Cells were cultured for days after transfection, and fixed with 4% paraformaldehyde in 0.1 m phosphate buffer After being washed with NaCl ⁄ Pi, they were incubated with the antibody against STAT5A_ FL or antibody against STAT5A_DE18 (1 : 100 dilution) in NaCl ⁄ Pi containing 0.1% Triton X-100 overnight at °C After three washes with NaCl ⁄ Pi, the cells were incubated with fluorescein isothiocyanate-conjugated or Alexa Fluor 546-conjugated anti-rabbit IgG (1 : 500 dilution; Invitrogen) for h at room temperature After washing and staining with 4¢,6-diamidino-2-phenylindole (DAPI) (Dojindo, Kumamoto, Japan), the cells on the cover glasses were mounted on glass slides in an aqueous mounting medium (GEL ⁄ MOUNT; Biomeda, Foster City, CA, USA) and examined under a fluorescence microscope (Olympus, Tokyo, Japan) HeLa cells stably expressing STAT5A_DE18–EGFP were cultured in glass-bottomed culture dishes (Iwaki, Tokyo, Japan), and organelles were stained with MitoTracker Orange CM-H2TMRos, ER-Tracker Red, and LysoTracker Red DND-99 (Invitrogen) Confocal laser microscopy was performed on live cells using a multitrack analysis (LSM 510 META; Carl Zeiss, Oberkochen, Germany) EGFP was excited using a 488 nm argon laser, MTT and cytotoxicity assays For MTT and cytotoxicity assays, · 104 cells were cultured in 96-well plates and transfected with control vector, pFlag–STAT5A_FL or pFlag–STAT5A_DE18, using Lipofectamine LTX MTT assays were performed using a Cell Counting Kit-8 (Dojindo) according to the manufacturer’s recommendations The absorbances at 429 or 600 nm were measured using a Multiskan Plus (Thermo Fisher Scientific, Waltham, MA, USA) Cytotoxicity assays were performed using a CytoTox-Glo Cytotoxicity Assay Kit (Promega) Luminescence was measured using a GENios (Tecan, Mannedorf, Switzerland) All experiments were repeated ă three times Reporter assay T47D cells were transfected with 0.5 lg of pFlag–STAT5A_FL, pFlag–STAT5A_DE18, or vector Simultaneously, 0.5 lg of a firefly luciferase reporter plasmid with the mouse b-casein promoter (pCasein-luc) and 0.25 lg of a Renilla luciferase control plasmid (pSV40-Rluc) were cotransfected using the Lipofectamine LTX and PLUS reagents (Invitrogen) At 24 h after transfection, the cells were treated with 10 ngỈmL)1 recombinant human PRL (Cedarlane Laboratories, Burlington, Canada) in serum-free medium for 24 h The cells were lysed with Passive Lysis Buffer (Promega), and the luciferase activities were measured using a Dual-Luciferase Reporter Assay System (Promega) and a MicroLumat LB96P Luminometer (Berthold Technologies, Bad Wildbad, Germany) All experiments were repeated three times Acknowledgements We greatly appreciate the gift of the T47D cell line from Dr J Kitawaki (Department of Obstetrics and Gynecology, Kyoto Prefectural University of Medicine) This work was supported in part by a grant from the Ministry of Education, Culture, Sports, Science and Technology, Japan (No 18500268 to M Tanaka) and a grant from the Research Institute for Neurological Diseases and Geriatrics, Kyoto Prefectural University of Medicine (to M Tanaka) References Darnell JE Jr, Kerr IM & Stark GR (1994) Jak-STAT pathways and transcriptional activation in response to FEBS Journal 276 (2009) 6312–6323 ª 2009 The Authors Journal compilation ª 2009 FEBS 6321 A novel variant form suppresses full-length STAT5A 10 11 12 13 14 15 Y Watanabe et al IFNs and other extracellular signaling proteins Science 264, 1415–1421 Levy DE & Darnell JE Jr (2002) Stats: transcriptional control and biological impact Nat Rev Mol Cell Biol 3, 651–662 Ihle JN (1996) STATs: signal transducers and activators of transcription Cell 84, 331–334 Hoey T & Schindler U (1998) STAT structure and function in signaling Curr Opin Genet Dev 8, 582–587 John S, Vinkemeier U, Soldaini E, Darnell JE Jr & Leonard WJ (1999) The significance of tetramerization in promoter recruitment by Stat5 Mol Cell Biol 19, 1910–1918 Brockman JL, Schroeder MD & Schuler LA (2002) PRL activates the cyclin D1 promoter via the Jak2 ⁄ Stat pathway Mol Endocrinol 16, 774–784 O’Shea JJ (1997) Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet? Immunity 7, 1–11 Markham K, Schuurmans C & Weiss S (2007) STAT5A ⁄ B activity is required in the developing forebrain and spinal cord Mol Cell Neurosci 35, 272–282 Mori H, Hanada R, Hanada T, Aki D, Mashima R, Nishinakamura H, Torisu T, Chien KR, Yasukawa H & Yoshimura A (2004) Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity Nat Med 10, 739–743 Lee JY, Muenzberg H, Gavrilova O, Reed JA, Berryman D, Villanueva EC, Louis GW, Leinninger GM, Bertuzzi S, Seeley RJ et al (2008) Loss of cytokine– STAT5 signaling in the CNS and pituitary gland alters energy balance and leads to obesity PLoS ONE 3, e1639 Tanaka M, Iijima N, Miyamoto Y, Fukusumi S, Itoh Y, Ozawa H & Ibata Y (2005) Neurons expressing relaxin ⁄ INSL in the nucleus incertus respond to stress Eur J Neurosci 21, 1659–1670 McGowan BM, Stanley SA, Smith KL, White NE, Connolly MM, Thompson EL, Gardiner JV, Murphy KG, Ghatei MA & Bloom SR (2005) Central relaxin-3 administration causes hyperphagia in male Wistar rats Endocrinology 146, 3295–3300 Miyamoto Y, Watanabe Y & Tanaka M (2008) Developmental expression and serotonergic regulation of relaxin ⁄ INSL7 in the nucleus incertus of rat brain Regul Pept 145, 54–59 Tanaka M, Watanabe Y & Yoshimoto K (2009) Regulation of relaxin gene expression via cAMP– PKA in a neuroblastoma cell line J Neurosci Res 87, 820–829 Kline JB, Roehrs H & Clevenger CV (1999) Functional characterization of the intermediate isoform of the human prolactin receptor J Biol Chem 274, 35461– 35468 6322 16 Fang F, Antico G, Zheng J & Clevenger CV (2008) Quantification of PRL ⁄ Stat5 signaling with a novel pGL4-CISH reporter BMC Biotechnol 8, 11 17 Lim CP & Cao X (2006) Structure, function, and regulation of STAT proteins Mol Biosyst 2, 536–550 18 Wang D, Stravopodis D, Teglund S, Kitazawa J & Ihle JN (1996) Naturally occurring dominant negative variants of Stat5 Mol Cell Biol 16, 6141–6148 19 Meyer J, Jucker M, Ostertag W & Stocking C (1998) ă Carboxyl-truncated STAT5b is generated by a nucleusassociated serine protease in early hematopoietic progenitors Blood 91, 1901–1908 20 Yamashita H, Iwase H, Toyama T & Fujii Y (2003) Naturally occurring dominant-negative Stat5 suppresses transcriptional activity of estrogen receptors and induces apoptosis in T47D breast cancer cells Oncogene 22, 1638–1652 21 Caldenhoven E, van Dijk TB, Solari R, Armstrong J, Raaijmakers JA, Lammers JW, Koenderman L & de Groot RP (1996) STAT3b, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription J Biol Chem 271, 13221–13227 22 Neculai D, Neculai AM, Verrier S, Straub K, Klumpp K, Pfitzner E & Becker S (2005) Structure of the unphosphorylated STAT5a dimer J Biol Chem 280, 40782–40787 23 Azam M, Erdjument-Bromage H, Kreider BL, Xia M, Quelle F, Basu R, Saris C, Tempst P, Ihle JN & Schindler C (1995) lnterleukin-3 signals through multiple isoforms of Stat5 EMBO J 14, 1402–1411 24 Oberdoerffer S, Moita LF, Neems D, Freitas RP, Hacohen N & Rao A (2008) Regulation of CD45 alternative splicing by heterogeneous ribonucleoprotein, hnRNPLL Science 321, 686–691 25 Mutze J, Roth J, Gerstberger R & Hubschle T (2007) ă ă Nuclear translocation of the transcription factor STAT5 in the rat brain after systemic leptin administration Neurosci Lett 417, 286–291 26 Lansbury PT & Lashuel HA (2006) A century-old debate on protein aggregation and neurodegeneration enters the clinic Nature 443, 774–779 27 Kopito RR (2000) Aggresomes, inclusion bodies and protein aggregation Trends Cell Biol 10, 524–530 28 Li SH & Li XJ (2004) Huntingtin–protein interactions and the pathogenesis of Huntington’s disease Trends Genet 20, 146–154 29 Yamanaka T, Miyazaki H, Oyama F, Kurosawa M, Washizu C, Doi H & Nukina N (2008) Mutant Huntingtin reduces HSP70 expression through the sequestration of NF-Y transcription factor EMBO J 27, 827–839 30 Kofoed EM, Hwa V, Little B, Woods KA, Buckway CK, Tsubaki J, Pratt KL, Bezrodnik L, Jasper H, Tepper A et al (2003) Growth hormone insensitivity FEBS Journal 276 (2009) 6312–6323 ª 2009 The Authors Journal compilation ª 2009 FEBS Y Watanabe et al associated with a STAT5b mutation New Engl J Med 349, 1139–1147 31 Hwa V, Little B, Adiyaman P, Kofoed EM, Pratt KL, Ocal G, Berberoglu M & Rosenfeld RG (2005) Severe growth hormone insensitivity resulting from total absence of signal transducer and activator of transcription 5b J Clin Endocrinol Metab 90, 4260–4266 32 Xu B, Kitawaki J, Koshiba H, Ishihara H, Kiyomizu M, Teramoto M, Kitaoka Y & Honjo H (2007) A novel variant form suppresses full-length STAT5A Differential effects of progestogens, by type and regimen, on estrogen-metabolizing enzymes in human breast cancer cells Maturitas 56, 142–152 33 Watanabe Y, Okui A, Mitsui S, Kawarabuki K, Yamaguchi T, Uemura H & Yamaguchi N (2004) Molecular cloning and tissue-specific expression analysis of mouse spinesin, a type II transmembrane serine protease Biochem Biophys Res Commun 324, 333–340 FEBS Journal 276 (2009) 6312–6323 ª 2009 The Authors Journal compilation ª 2009 FEBS 6323 ... 6317 A novel variant form suppresses full-length STAT 5A Y Watanabe et al A B C D E F G Fig Aggregate formation of STAT 5A_ DE18 and STAT 5A_ FL (A) pFlag–STAT 5A_ DE18 or control vector was transfected... the brainstem and coaggregates with STAT 5A_ full length (STAT 5A_ FL) Furthermore, the expression of this variant suppresses the activity of STAT 5A Results Isolation of a novel STAT 5A splicing variant. .. results are consistent with the hypothesis that aggregation of STAT 5A_ DE18 suppresses the transcriptional activity of STAT 5A Discussion We isolated a novel STAT 5A splicing variant from the mouse brainstem